Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LG3Q
|
|||
| Drug Name |
PLX-PAD cell therapy
|
|||
| Indication | Critical limb ischemia [ICD-11: BD4Y; ICD-9: 459.89] | Phase 3 | [1] | |
| Peripheral vascular disease [ICD-11: BD4Z; ICD-10: I73, I73.9] | Phase 2 | [2] | ||
| Company |
Pluristem Therapeutics Haifa, Israel
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01679990) Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.